Switch theme
Sign up to access all valuation multiples
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
2015
112
LTM Revenue $23.5M
LTM EBITDA -$108M
-$7.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Foghorn Therapeutics has a last 12-month revenue of $23.5M and a last 12-month EBITDA of -$108M.
In the most recent fiscal year, Foghorn Therapeutics achieved revenue of $22.6M and an EBITDA of -$97.2M.
Foghorn Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Foghorn Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $34.2M | $22.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$104M | -$97.2M | XXX | XXX | XXX |
| EBITDA Margin | -306% | -430% | XXX | XXX | XXX |
| Net Profit | -$109M | -$98.4M | XXX | XXX | XXX |
| Net Margin | -319% | -435% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Foghorn Therapeutics's stock price is $4.
Foghorn Therapeutics has current market cap of $200M, and EV of -$7.0M.
See Foghorn Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$7.0M | $200M | XXX | XXX | XXX | XXX | $-1.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Foghorn Therapeutics has market cap of $200M and EV of -$7.0M.
Foghorn Therapeutics's trades at -0.3x LTM EV/Revenue multiple, and 0.1x LTM EBITDA.
Analysts estimate Foghorn Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Foghorn Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$7.0M | XXX | XXX | XXX |
| EV/Revenue | -0.3x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | XXX | XXX |
| P/E | -2.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFoghorn Therapeutics's NTM/LTM revenue growth is 16%
Foghorn Therapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Foghorn Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Foghorn Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Foghorn Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -34% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -430% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -414% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 125% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 418% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 544% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Foghorn Therapeutics acquired XXX companies to date.
Last acquisition by Foghorn Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Foghorn Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Foghorn Therapeutics founded? | Foghorn Therapeutics was founded in 2015. |
| Where is Foghorn Therapeutics headquartered? | Foghorn Therapeutics is headquartered in United States of America. |
| How many employees does Foghorn Therapeutics have? | As of today, Foghorn Therapeutics has 112 employees. |
| Who is the CEO of Foghorn Therapeutics? | Foghorn Therapeutics's CEO is Mr. Adrian Gottschalk. |
| Is Foghorn Therapeutics publicy listed? | Yes, Foghorn Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Foghorn Therapeutics? | Foghorn Therapeutics trades under FHTX ticker. |
| When did Foghorn Therapeutics go public? | Foghorn Therapeutics went public in 2020. |
| Who are competitors of Foghorn Therapeutics? | Similar companies to Foghorn Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Foghorn Therapeutics? | Foghorn Therapeutics's current market cap is $200M |
| What is the current revenue of Foghorn Therapeutics? | Foghorn Therapeutics's last 12-month revenue is $23.5M. |
| What is the current EBITDA of Foghorn Therapeutics? | Foghorn Therapeutics's last 12-month EBITDA is -$108M. |
| What is the current EV/Revenue multiple of Foghorn Therapeutics? | Current revenue multiple of Foghorn Therapeutics is -0.3x. |
| What is the current EV/EBITDA multiple of Foghorn Therapeutics? | Current EBITDA multiple of Foghorn Therapeutics is 0.1x. |
| What is the current revenue growth of Foghorn Therapeutics? | Foghorn Therapeutics revenue growth between 2023 and 2024 was -34%. |
| Is Foghorn Therapeutics profitable? | Yes, Foghorn Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
